Overview

Phase II Clinical Trial to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops in Patients With Dry Eye Disease

Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) in Patients with Dry Eye Disease.
Phase:
Phase 2
Details
Lead Sponsor:
SCAI Therapeutics
Treatments:
Cyclosporine
Cyclosporins
Ophthalmic Solutions